Novocure

ASCO 2023 – Novocure sinks as Lunar’s limitations become clear
ASCO 2023 – Novocure sinks as Lunar’s limitations become clear
EP Vantage
ASCO 2023
Novocure
tumor treating fields
Flag link:
Novocure shares soar on positive lung cancer data
Novocure shares soar on positive lung cancer data
BioPharma Dive
Novocure
lung cancer
Medtech
devices
clinical trials
Flag link:
The FDA Will Soon Give These 3 Healthcare Companies the Green Light
The FDA Will Soon Give These 3 Healthcare Companies the Green Light
Motley Fool
Novavax
vaccines
COVID-19
Axsome Therapeutics
FDA
Novocure
lung cancer
Flag link:
FDA ends summer with fresh batch of breakthrough device designations
FDA ends summer with fresh batch of breakthrough device designations
Medtech Dive
devices
Medtech
FDA
Novocure
liver cancer
CellMax Life
Endosound
ImpediMed
Auctus Surgical
Madorra
MicroTransponder
breakthrough device
Flag link:
NovoCure, Merck Team Up on Phase II Lung Cancer Trial
NovoCure, Merck Team Up on Phase II Lung Cancer Trial
BioSpace
Merck
Novocure
clinical trials
tumor treating fields
Keytruda
non-small cell lung cancer
Flag link:
11 Medical Devices Recently Approved by FDA
11 Medical Devices Recently Approved by FDA
Medical Devices and Diagnostics Industry
FDA
devices
Triluron
Fidia Farmaceutici
Cerene Cryotherapy Device
Channel Medsystems
therascreen FGFR RGQ PCR Kit
Qiagen
TherOx DownStream System
TherOx
TransPyloric Shuttle/TransPyloric Shuttle Delivery Device
BAROnova
XVIVO Perfusion System (XPS)
XVIVO Perfusion
Tack Endovascular System
Intact Vascular
Vici Venous Stent System
Boston Scientific
Lotus Edge
Neuroform Atlas
Stryker
NovoTTF-100L System
Novocure
Flag link:
Novocure Wins FDA Approval for First Mesothelioma Treatment in 15 Years
Novocure Wins FDA Approval for First Mesothelioma Treatment in 15 Years
BioSpace
Novocure
NovoTTF-100L
mesothelioma
Flag link:
Novocure launches pivotal ovarian cancer trial
Novocure launches pivotal ovarian cancer trial
Drug Delivery Business News
Novocure
devices
ovarian cancer
platinum-resistant ovarian cancer
clinical trials
tumor treating fields
Flag link:
New Study Suggests Tumor Treating Fields Can Increase Progression-Free Survival in Pancreatic Cancer
New Study Suggests Tumor Treating Fields Can Increase Progression-Free Survival in Pancreatic Cancer
CP Wire
Novocure
pancreatic cancer
Flag link:
New Study Suggests Tumor Treating Fields Can Increase Progression-Free Survival in Pancreatic Cancer
Novocure
pancreatic cancer
Flag link:
Lessons learned from going live on Facebook with a branded drug
Lessons learned from going live on Facebook with a branded drug
Medical Marketing and Media
Novocure
Optune
Facebook
social media
Flag link:
Novocure touts top-line data from Ph2 mesothelioma trial
Novocure touts top-line data from Ph2 mesothelioma trial
Drug Delivery Business News
Novocure
clinical trials
mesothelioma
humanitarian device exemption
tumor treating fields
devices
Flag link:
Study: Novocure’s Optune, drug combo adds months to the lives of GBM patients
Study: Novocure’s Optune, drug combo adds months to the lives of GBM patients
Drug Delivery Business News
Novocure
Optune
glioblastoma multiforme
Flag link:
Novocure wins FDA nod for pivotal pancreatic cancer trial
Novocure wins FDA nod for pivotal pancreatic cancer trial
Drug Delivery Business News
Novocure
FDA
pancreatic cancer
TTFields
Flag link:
The Fastest Growing Cancer Company You've Never Heard Of
The Fastest Growing Cancer Company You've Never Heard Of
Motley Fool
devices
Novocure
tumor treating fields
cancer
TTFields
glioblastoma
ovarian cancer
pancreatic cancer
lung cancer
Flag link:
Novocure enrolls 1st patient in phase III brain metastases trial
Novocure enrolls 1st patient in phase III brain metastases trial
Mass Device
Novocure
devices
brain metastases
non-small cell lung cancer
Flag link:
11 biopharma execs & experts look back on 2015: A record year for record-breaking
11 biopharma execs & experts look back on 2015: A record year for record-breaking
BioPharma Dive
Sanofi
Pfenex
inVentiv
Novocure
Accenture
Boehringer Ingelheim
Flag link:
NovoCure’s cancer therapy effective in late-stage study
NovoCure’s cancer therapy effective in late-stage study
Mass Device
Novocure
Optune
brain cancer
glioblastoma multiforme
devices
Flag link:
NovoCure sets terms on $206m IPO
NovoCure sets terms on $206m IPO
Mass Device
IPOs
Novocure
devices
Optune
tumors
Flag link:
FDA clears first-of-a-kind device for brain cancer
FDA clears first-of-a-kind device for brain cancer
FDA
brain cancer
Novocure
Flag link:

Pages